Literature DB >> 21659854

Biologic modulators in allergic and autoinflammatory diseases.

Lori Broderick1, Louanne M Tourangeau, Arthur Kavanaugh, Stephen I Wasserman.   

Abstract

PURPOSE OF REVIEW: The advent of molecular techniques has resulted in the ability to tailor medications to specific protein targets. This review will emphasize several biological therapies, specifically directed toward cytokine receptors and inhibitors, and their role in the treatment of atopic and autoinflammatory diseases. RECENT
FINDINGS: Translational research and the identification of the molecular pathophysiology of diseases have led to more targeted treatment approaches. The biologic modulators encompassing monoclonal antibodies as cytokine inhibitors, receptor blocking antibodies, and new fusion receptors are now being applied to diseases beyond their original application.
SUMMARY: The expanded use of biological therapies has experienced success in the treatment of numerous disorders, especially in subsets of patients with disease that has been refractory to conventional therapies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21659854      PMCID: PMC3154953          DOI: 10.1097/ACI.0b013e328348a882

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  41 in total

1.  Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.

Authors:  H Milgrom; R B Fick; J Q Su; J D Reimann; R K Bush; M L Watrous; W J Metzger
Journal:  N Engl J Med       Date:  1999-12-23       Impact factor: 91.245

2.  Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis.

Authors:  Laura Obici; Antonella Meini; Marco Cattalini; Silvana Chicca; Marco Galliani; Simona Donadei; Alessandro Plebani; Giampaolo Merlini
Journal:  Ann Rheum Dis       Date:  2010-12-20       Impact factor: 19.103

3.  Characterization of an anaphylactoid reaction to omalizumab.

Authors:  David H Dreyfus; Christopher C Randolph
Journal:  Ann Allergy Asthma Immunol       Date:  2006-04       Impact factor: 6.347

4.  Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects.

Authors:  Jill A Poole; Jianfeng Meng; Mitchell Reff; Mary C Spellman; Lanny J Rosenwasser
Journal:  J Allergy Clin Immunol       Date:  2005-10       Impact factor: 10.793

Review 5.  Anti-CD23.

Authors:  Lanny J Rosenwasser; Jianfeng Meng
Journal:  Clin Rev Allergy Immunol       Date:  2005-08       Impact factor: 8.667

6.  Treatment of patients with the hypereosinophilic syndrome with mepolizumab.

Authors:  Marc E Rothenberg; Amy D Klion; Florence E Roufosse; Jean Emmanuel Kahn; Peter F Weller; Hans-Uwe Simon; Lawrence B Schwartz; Lanny J Rosenwasser; Johannes Ring; Elaine F Griffin; Ann E Haig; Paul I H Frewer; Jacqueline M Parkin; Gerald J Gleich
Journal:  N Engl J Med       Date:  2008-03-16       Impact factor: 91.245

Review 7.  Anti-IgE therapy.

Authors:  Jaine Brownell; Thomas B Casale
Journal:  Immunol Allergy Clin North Am       Date:  2004-11       Impact factor: 3.479

8.  Effect of anti-IgE therapy in patients with peanut allergy.

Authors:  Donald Y M Leung; Hugh A Sampson; John W Yunginger; A Wesley Burks; Lynda C Schneider; Cornelis H Wortel; Frances M Davis; John D Hyun; William R Shanahan
Journal:  N Engl J Med       Date:  2003-03-10       Impact factor: 91.245

9.  Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis.

Authors:  Paul Chervinsky; Thomas Casale; Robert Townley; Ita Tripathy; Simon Hedgecock; Angel Fowler-Taylor; Henry Shen; Howard Fox
Journal:  Ann Allergy Asthma Immunol       Date:  2003-08       Impact factor: 6.347

Review 10.  Hereditary auto-inflammatory disorders and biologics.

Authors:  Leigh D Church; Sarah M Churchman; Philip N Hawkins; Michael F McDermott
Journal:  Springer Semin Immunopathol       Date:  2006-05-04
View more
  1 in total

Review 1.  Role of fibrinogen in cerebrovascular dysfunction after traumatic brain injury.

Authors:  Nino Muradashvili; David Lominadze
Journal:  Brain Inj       Date:  2013-09-24       Impact factor: 2.311

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.